Lyell Immunopharma (Lyell Immunopharma) Price-to-Operating-Cash-Flow : (As of Apr. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Price-to-Operating-Cash-Flow?

As of today (2024-04-27), Lyell Immunopharma's share price is $2.17. Lyell Immunopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65. Hence, Lyell Immunopharma's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Lyell Immunopharma's Price-to-Operating-Cash-Flow or its related term are showing as below:

LYEL's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Lyell Immunopharma's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.16. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.00% per year.

During the past 5 years, Lyell Immunopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 5.00% per year. The lowest was 5.00% per year. And the median was 5.00% per year.

Lyell Immunopharma Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Lyell Immunopharma's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Price-to-Operating-Cash-Flow Chart

Lyell Immunopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Lyell Immunopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Lyell Immunopharma's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Lyell Immunopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyell Immunopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Price-to-Operating-Cash-Flow falls into.

Lyell Immunopharma Price-to-Operating-Cash-Flow Calculation

Lyell Immunopharma's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	2.17	/	-0.653
	=

Lyell Immunopharma's Share Price of today is $2.17.
Lyell Immunopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Lyell Immunopharma Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyell Immunopharma (Lyell Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, South San Francisco, CA, USA, 94080

Website

https://www.lyell.com

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Executives

Richard Klausner	director, officer: Executive Chairman	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang	officer: Chief Business Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson	officer: Chief Legal Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson	officer: Chief Medical Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee	officer: Chief Scientific Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans	director, officer: Chief Executive Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill	officer: Chief Technical Ops. Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton	officer: Chief Financial Officer	46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631